AVLN: the balance sheet

MyFinsight

Avalyn Pharma Inc. (AVLN)

For the quarter ending 2026-03-31, AVLN has $135,663K in assets. $27,687K in debts. $92,310K in cash and cash equivalents.

Balance Sheets	2026-03-31
Cash and cash equivalents	92,310
Marketable securities, current	30,817
Prepaid expenses and other current assets	6,860
Total current assets	129,987
Total property and equipment	1,373
Less accumulated depreciation	117
Property and equipment, net	1,256
Operating lease right-of-use asset	1,421
Other assets	2,999
Total noncurrent assets	5,676
Total assets	135,663

Accounts payable	3,147
Accrued liabilities	8,133
Operating lease liability	507
Total current liabilities	11,787
Term loan	14,808
Operating lease liability, noncurrent	1,092
Total liabilities	27,687
Redeemable convertible preferred stock-Series APreferred Stock	49,176
Redeemable convertible preferred stock-Series BPreferred Stock	35,376
Redeemable convertible preferred stock-Series CPreferred Stock	174,494
Redeemable convertible preferred stock-Series C2Preferred Stock	13,406
Redeemable convertible preferred stock-Series DPreferred Stock	99,769
Common stock, 0.001 par value 585,000,000 and 575,000,000 shares authorized as of march 31, 2026 and december 31, 2025, respectively 1,232,442 and 1,227,186 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively	24
Additional paid-in capital	27,950
Accumulated other comprehensive income	12
Accumulated deficit	-292,231
Total stockholders' deficit	-264,245
Total liabilities, redeemable convertible preferred stock and stockholders' deficit	135,663

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.